1212 · 30/07/2026 15:51:55 · Announcement #97110 · View on Saudi Exchange

Astra Industrial Group announces its Interim Financial results for the Period Ending on 2026-06-30 ( Six Months )

Element ListCurrent QuarterSimilar quarter for previous year%ChangePrevious Quarter% Change
Sales/Revenue 775,872,842715,112,3018.496790,909,047-1.901
Gross Profit (Loss) 384,226,035326,588,98317.648385,259,335-0.268
Operational Profit (Loss) 194,128,148203,614,307-4.658192,085,7151.063
Net Profit (Loss) Attributable to Shareholders of the Issuer 192,062,164174,924,4399.797173,138,80910.929
Total Comprehensive Income Attributable to Shareholders of the Issuer 226,525,778174,796,30529.594172,515,68931.307
All figures are in (Actual) Saudi Arabia, Riyals
Element ListCurrent PeriodSimilar period for previous year%Change
Sales/Revenue 1,566,781,8891,548,840,4711.158
Gross Profit (Loss) 769,485,370699,186,98610.054
Operational Profit (Loss) 386,213,863392,915,422-1.705
Net Profit (Loss) Attributable to Shareholders of the Issuer 365,200,973346,795,5355.307
Total Comprehensive Income Attributable to Shareholders of the Issuer 399,041,467351,519,43113.519
Total Shareholders Equity (after Deducting Minority Equity) 3,081,032,1492,635,325,50916.912
Profit (Loss) per Share 4.574.33
All figures are in (Actual) Saudi Arabia, Riyals
Element ListAmountPercentage of the capital (%)
Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value --
All figures are in (Actual) Saudi Arabia, Riyals
Element ListExplanation
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is Sales increase in general due to:

Increase in Sales in Pharmaceuticals segment.

While noting that there is decrease in Sales in Steel industries segment.The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is Net profit Increases in general due to:

1. Increase in Gross Profit in all segments.

2. Increase in Other income, net in others segment.

3. Decrease in Finance costs in all segments.

While noting that during similar period last year, there were lower General and administrative expenses in Steel industries segment due to reversal of excess accrual.The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is Sales decrease in general due to:

Decrease in Sales in Steel industries segment.The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is Net profit Increases in general due to:

1. Increase in Other income, net in Others segment.

2. Decrease in Expense for impairment of financial assets mainly in Steel industries segment.The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is Sales increases in general due to:

Increase in Sales in Pharmaceuticals segment.The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is Net profit Increases in general due to:

1. Increase in Gross Profit in all segments.

2. Decrease in Finance costs in all segments.

While noting that during similar period last year, there were lower General and administrative expenses in Steel industries segment due to reversal of excess accrual.Statement of the type of external auditor's report Unmodified conclusionComment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) N\AReclassification of Comparison Items N\AAdditional Information Net Shareholders’ Equity at the end of the period was SR 3,080,392,221/- compared to SR 2,656,733,760/- at the end of the similar period last year with an increase of 16%.

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.